Extedo adds two to management board

Directors will be based in Germany and US respectively

Extedo, a provider of eRegulatory Affairs solutions to life sciences firms, has added Martin Schmid and Joseph Dude to its management board.

Schmid joins the organisation as president and now shares day-to-day operational responsibilities with chief executive Tore Bergsteiner.

Dude has taken the position of managing director at Extedo Inc in the US, to support the organisation’s expansion in North America.

Schmid will head up the global marketing and sales organisation as well as the Product Management Unit, which are key areas for Extedo. He will be based in Ottobrunn, Germany.

Schmid has more than 15 years of experience in management consulting, marketing and sales.

Dude will be based in West Chester, PA. He has more than 20 years of experience in the IT services and software industries with Prime Technology Group, Glemser Technologies, First Consulting Group and Thomson Financial.

You may also like

Regulatory

Novartis' Kisqali plus ET bags FDA approval for HR+/HER2- breast cancer

The decision comes off the back of the Phase III NATALEE clinical trial, which diminished the risk of disease recurrence by 25.1%
Sustainability

ten23 health achieves B Corp status

The acknowledgement makes the ten23 the first biotech CDMO to receive this status
Regulatory

Roche's cancer immunotherapy Tecentriq Hybreza bags FDA approval

The drug first and only subcutaneous PD-(L)1 inhibitor available for patients with certain types of lung, skin, liver and soft tissue cancers
Regulatory

How the EU's AI Act of 2024 will impact businesses using the technology

The legally binding rules on AI use aim to enhance the reliability and safety of the technology's implementation globally
Regulatory

SeaBeLife's SBL01 acute liver failure drug candidate receives ODD from the EMA

The small molecule acts as a necrosis and ferroptosis inhibitor, allowing for the protection and restoration of liver cells in those with acute liver failure
Regulatory

Johnson & Johnson submits nipocalimab application to the FDA following positive Phase III results

The drug — in combination with the standard of care regimen — was able to exhibit sustained disease control over the 24 week trial period
Regulatory

Padcev plus Keytruda approved for advanced urothelial cancer by the EC

The therapeutic combination will now be named as the first-line, standard of care treatment for metastatic or advanced bladder cancer
Subscribe now